Antibody Contract Manufacturing Market is Anticipated to Reach USD 49.1 Billion by 2035

According to a recently published report by Roots Analysis, rapid advancements in bioprocessing technologies, increasing demand for outsourced manufacturing, expanding antibody pipelines and the growing complexity of biologics production, is driving significant growth in antibody contract manufacturing market

Global Antibody Contract Manufacturing Market Overview

The global antibody contract manufacturing market is expected to reach around USD 49.1 billion by 2035, growing at a CAGR of 9.7% during the forecast period till 2035.

Over the past decade, antibody contract manufacturing has become an increasingly important component of the biopharmaceutical industry, supported by the expanding development of monoclonal antibodies, ADCs, bispecific antibodies and other complex biologics. As pharmaceutical and biotechnology companies seek to accelerate development timelines and reduce the capital burden associated with in-house production, outsourcing to specialized CMOs has gained significant momentum. These providers offer expertise across cell-line development, upstream and downstream processing, analytical testing, formulation and fill-finish services. This enables clients to advance antibody candidates from early development through commercial manufacturing.

The growing number of antibody-based therapies entering clinical development and reaching regulatory approval is further strengthening demand for outsourced manufacturing capacity. In addition, the need for scalable production platforms, advanced bioprocessing technologies, flexible manufacturing infrastructure, and compliance with increasingly stringent regulatory requirements is encouraging companies to establish long-term partnerships with antibody CMOs. Moreover, continued investment in biologics research, the expansion of antibody pipelines, rising demand for personalized therapies, and the increasing complexity of next-generation antibodies are expected to support sustained growth in the antibody contract manufacturing market over the medium to long term.

Browse ~220 figures and 290+ market data tables spread across ~300 pages and detailed Table of Content on “Global Antibody Contract Manufacturing Market”, till 2035 by Type of Antibody Manufactured (Monoclonal Antibodies and Bispecific Antibodies), Type of Product (APIs and FDFs), Type of Expression System Used (Mammalian Expression System and Microbial Expression System), Scale of Operation (Clinical Scale and Commercial Scale), Therapeutic Area (Oncological Disorders, Cardiovascular Disorders, Metabolic Disorders, Infectious Diseases, Autoimmune Disorders, Neurological Disorders, Genetic Disorders and Other Disorders), Company Size (Small Companies, Mid-sized Companies, and Large and Very Large Companies) and Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)- https://www.rootsanalysis.com/reports/antibody-cmo-market/295.html

Market Drivers

Several factors are propelling the growth of global antibody contract manufacturing market. One of the key factors driving the future of antibody CMO market is the growing expansion in the domain. Leading antibody contract manufacturers are investing heavily in expanding biologics manufacturing capacity to accommodate growing demand from pharmaceutical and biotechnology companies. For example, in February 2026, FUJIFILM Biotechnologies inaugurated its expanded biomanufacturing facility in Teesside, UK, following an investment of approximately £400 million. The 110,000-square-foot facility incorporates 2,000-L and 5,000-L single-use bioreactors, providing total capacity of up to 19,000 L for small- and mid-scale antibody manufacturing. Further, the pharmaceutical companies are increasingly entering into long-term manufacturing agreements with CDMOs to secure reliable production capacity while reducing the need for internal capital investment. For instance, in January 2026, LOTTE Biologics and Rakuten Medical entered into a biopharmaceutical contract manufacturing agreement. Through this collaboration LOTTE Biologics will provide advanced monoclonal antibody CMO services to support Rakuten Medical’s global clinical development and commercialization activities. Consequently, owing to such collaborations, the antibody CMO market is anticipated to witness substantial growth in the foreseeable future.

Market Restraints

While the global antibody contract manufacturing market is experiencing substantial growth, there are certain restraints that can hinder the growth of this industry. One of the primary challenges is high capital investment needs. Establishing and maintaining state-of-the-art manufacturing facilities for antibody production requires substantial upfront capital for specialized equipment, cleanrooms, and advanced technologies like single-use systems. This financial barrier limits entry for new players, strains resources for existing CDMOs, and can hinder scalability, especially amid rising costs for quality assurance and emissions compliance. Further, the antibody CMO market faces significant hurdles due to rigorous approval processes enforced by authorities like the FDA and EMA. This demands extensive documentation, compliance with GMP standards, and thorough validation of manufacturing processes.

Growth Factors

Despite the aforementioned restraints, several growth factors continue to drive the global antibody contract manufacturing market forward. One notable factor is the rising demand for personalized medicine, which offers significant opportunities for antibody contract manufacturers as therapies are increasingly tailored to patients based on their genetic profiles, biomarkers, disease characteristics, and other individual factors. This trend is driving demand for customized antibodies and antibody-based therapeutics, creating opportunities for contract manufacturers with flexible and scalable production capabilities, specialized expertise, and accelerated development timelines. In addition, pharmaceutical companies are increasingly seeking integrated, end-to-end supply chain solutions to streamline development and manufacturing activities. As a result, one-stop-shop providers offering comprehensive services across antibody discovery, development, process optimization, manufacturing, and related supply chain functions are becoming increasingly attractive strategic partners. This shift toward integrated outsourcing is expected to increase outsourcing volumes, strengthen long-term collaborations, and support recurring revenue generation for contract manufacturers. Owing to the aforementioned factors, it can be anticipated that the global antibody CMO market will flourish remarkably in the foreseeable future.

Global Antibody Contract Manufacturing Market Segments

Based on the type of antibody manufactured, the market is segmented into monoclonal antibodies and bispecific antibodies

• The monoclonal antibodies segment led the antibody contract manufacturing market, capturing the largest revenue share of 95% in the current year.
• The bispecific antibodies segment is anticipated to grow at a higher CAGR of 11.0%, during the forecast period.

Based on the type of product, the market is segmented into APIs and FDFs.

• The APIs segment led the antibody contract manufacturing market, capturing the largest revenue share of around 60% in the current year.
• The FDFs segment is anticipated to grow at a higher CAGR of 10.6%, during the forecast period.

Based on the type of expression system used, the market is segmented into mammalian expression system and microbial expression system.

• The mammalian expression system segment led the antibody contract manufacturing market, capturing the largest revenue share of around 75% in the current year.
• The mammalian expression system segment is anticipated to grow at a higher CAGR of 10.0%, during the forecast period.

Based on the scale of operation, the market is segmented into clinical scale and commercial scale.

• The commercial scale segment led the antibody contract manufacturing market, capturing the largest revenue share of around 90% in the current year.
• The commercial scale segment is anticipated to grow at a higher CAGR of 10.0%, during the forecast period.

Based on the therapeutic area, the market is segmented into oncological disorders, cardiovascular disorders, metabolic disorders, infectious diseases, autoimmune disorders, neurological disorders, genetic disorders and other disorders.

• The oncological disorders segment led the antibody contract manufacturing market, capturing the largest revenue share of around 35% in the current year.
• The oncological disorders segment is anticipated to grow at a higher CAGR of 10.5%, during the forecast period.

Based on the company size, the market is segmented into small companies, mid-sized companies, and large and very large companies.

• The large and very large companies segment led the antibody contract manufacturing market, capturing the largest revenue share of around 80% in the current year.
• The small companies segment is anticipated to grow at a higher CAGR of 15.3%, during the forecast period.

Based on geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World.

• Asia-Pacific dominated the antibody contract manufacturing market, accounting for the largest revenue share of around 45% in the current year.
• The antibody contract manufacturing market in Asia-Pacific is anticipated to demonstrate a higher growth rate of 10.8% during the forecast period.

Key Companies Profiled

The global antibody contract manufacturing market report also includes detailed profiles of key contract manufacturers (listed below) that are engaged in the antibody contract manufacturing domain:

• AGC Biologics
• Aldevron
• Axplora (formerly Novasep)
• Emergent BioSolutions
• Eurofins
• FUJIFILM Biotechnologies
• KBI Biopharma
• Lonza
• Nitto Avecia Pharma Services
• Pierre Fabre
• Samsung BioLogics
• Synthon
• Thermo Fisher Scientific

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/antibody-cmo-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com